Company: PTPI
Filing Date: 2025-03-18
Form Type: DEF 14A
Source: 0001104659-25-025104
Chunk: 43

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-18
Form: DEF 14A
Chunk 43
---
 29,929,668 shares of Common
Stock outstanding. For purposes of illustration, if the Reverse Stock Split is effected at a ratio of 1-for-250 or 1-for-500, the number
of issued and outstanding shares of Common Stock after the Reverse Stock Split would be approximately 119,718 shares and 59,859 shares,
respectively.

We are currently authorized
to issue a maximum of 250,000,000 shares of our Common Stock. As of the Record Date, there were 29,929,668 shares of our Common Stock
issued and outstanding. Although the number of authorized shares of our Common Stock will not change as a result of the Reverse Stock
Split, the number of shares of our Common Stock issued and outstanding will be reduced in proportion to the ratio selected by the Board.
Thus, the Reverse Stock Split will effectively increase the number of authorized and unissued shares of our Common Stock available for
future issuance by the amount of the reduction effected by the Reverse Stock Split.

Following the Reverse Stock
Split, the Board will have the authority, subject to applicable securities laws, to issue all authorized and unissued shares without further
stockholder approval, upon such terms and conditions as the Board deems appropriate. We do not currently have any plans, proposals or
understandings to issue the additional shares that would be available if the Reverse Stock Split is approved and effected, but some of
the additional shares underlie warrants, which could be exercised after the Reverse Stock Split Charter Amendment is effected.

Effects of the Reverse Stock Split on Outstanding Equity Awards and Plans.

If the Reverse Stock Split
is effected, the terms of equity awards granted under our Amended and Restated Petros Pharmaceuticals, Inc. 2020 Omnibus Incentive Compensation Plan (the “2020 Plan”), including (i) the number of shares and type of Common Stock
(or the securities or property) which thereafter may be made the subject of awards; (ii) the number of shares and type of Common
Stock (or other securities or property) subject to outstanding awards; (iii) the number of shares and type of Common Stock (or other
securities or property) specified as the annual per-participant limitation under the 2020 Plan; (iv) the option price of each outstanding
stock option; (v) the amount, if any, paid for forfeited shares in accordance with the terms of the 2020 Plan; and (vi) the
number of or exercise price of